研報掘金丨西部證券:比亞迪23年業績符預期,3月銷量亮眼,維持“買入”評級
西部證券研報指出,比亞迪(002594.SZ)2023年業績符合預期,3月銷量亮眼,伴隨二季度新車&新技術平台的陸續發佈,有望開啟新一輪向上週期,維持“買入”評級。2023年公司銷量突破300萬輛,毛利率同比優化。公司銷量大幅提升,帶動收入和業績高增並達到歷史新高。春節後公司陸續推出秦PLUS等多款榮耀款車型,定價普遍下降2-3萬元。比亞迪3月實現銷量30.25萬輛,較2月環比提高147%,其中出口3.84萬輛。該行預計公司將於Q2上市秦系新車/海洋生物新車,與秦PLUS形成雙代同堂搶佔A級市場。新車型方面,預計海獅07、仰望U7、騰勢Z9GT 等全新車型有望貢獻較高銷量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.